It is. But that doesn't change the fundamentals of the company and its clinical pipeline/current trials/results/partnerships/potential. It is very interesting the market has allowed the sp to drop back to these levels.. For me it's another opportunity to buy at the levels where I missed an entry last year. I'm quite confident that things will pickup and these prices will be a distant memory.
We all know that investments in biotech can be volatile, high risk high reward - And that trend reversals can come quickly. Risk to reward ratio seems to be in our favour at these prices with the upcoming year.
Only time will tell.
Did you HODL?, page-63
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.025(7.46%) |
Mkt cap ! $55.68M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.0¢ | 31.0¢ | $69.62K | 219.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 37054 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 36751 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
31.5¢ |
Change
-0.025 ( 5.32 %) |
||||
| Open | High | Low | Volume | ||
| 33.5¢ | 33.5¢ | 31.0¢ | 58449 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| CYP (ASX) Chart |